At iQ Biosciences, we’re proud to collaborate with a select group of consultants whose expertise and professionalism align with our own high standards. These individuals are deeply familiar with our work and have been valued collaborators across a range of scientific initiatives. By featuring them here, we aim to provide our clients and peers with access to trusted experts who can offer complementary guidance and support in their research and development efforts.
Bill Mallet
Founder and Managing Partner, Pedalion Bio
Bill has performed discovery research, lead molecule selection, and pre-clinical development of biologics since 2002. He has helped build multiple therapeutic platforms, including antibody-drug conjugates (ADCs) employing novel cytotoxic and immune-stimulating payloads and conjugation technologies, and bispecific T-cell engagers. He is an expert in target selection, antibody discovery, pre-clinical lead selection, and IND-enabling studies and regulatory document preparation. Additionally, Bill has built and led teams in diverse settings, from start-ups to established biopharma.
Marque Todd
President/Owner,
Marque is an independent consultant specializing in early and late stage non clinical regulatory toxicology strategy and program execution with extensive experience in biotherapeutic drug development for oncology, immunology and inflammation, metabolic, and cardiovascular diseases, and for small molecule programs in oncology. She is responsible for full or partial oversight of nonclinical toxicology program strategy/execution and dossier preparation to meet key milestones including IND filings, FDA and global health authority meetings, and product registration.
